A *Plasmodium falciparum* S33 proline aminopeptidase is associated with changes in erythrocyte deformability

Fabio L. da Silva^{a,b,*,¶}, Matthew WA Dixon^{c¶}, Colin M. Stack^{d¶}, Franka Teuscher^b, Elena Taran^{e,f}, Malcolm K. Jones^g, Erica Lovas^{g,†}, Leann Tilley^c, Christopher L Brown^{h,i}, Katharine R. Trenholme^{b,j}, John P. Dalton^{a,k}, Donald L. Gardiner^{b,i} and Tina S. Skinner-Adams^{h,i,*}

^aInstitute of Parasitology, McGill University, Canada

^bQIMR Berghofer Medical Research Institute, Australia

^cDepartment of Biochemistry and Molecular Biology, Bio21 Institute, and ARC Centre of Excellence for Coherent X-Ray Science, University of Melbourne, Australia

^dSchool of Science and Health, University of Western Sydney, Australia

^eAustralian Institute for Bioengineering & Nanotechnology, University of Queensland, Australia

^fThe Australian National Fabrication Facility, Queensland Node, Brisbane, Australia

^gSchool of Veterinary Sciences, University of Queensland, Australia

^hSchool of Natural Sciences, Griffith University. Brisbane, Queensland 4111, Australia

ⁱEskitis Institute for Drug Discovery, Griffith University, Queensland, Australia

^jSchool of Medicine. University of Queensland, Australia

^kSchool of Biological Sciences, Queen's University Belfast, Northern Ireland.

*Corresponding author

Eskitis Institute for Drug Discovery, Griffith University, 46 Don Young Rd Nathan, Queensland, Australia; Tel: 61 37354417; E-mail: t.skinner-adams@griffith.edu.au (TS. Skinner-Adams)

25 'Present address, Fabio L. da Silva

26 Institute of Biology Valrose, Université de Nice-Sophia, F-06108 Nice, France

27

28 'Present address, Erica Lovas

29 Centre for Microscopy & Microanalysis, University of Queensland, Australia

30

31 ¶ These authors contributed equally to this work

32

Abstract

Infection with the apicomplexan parasite *Plasmodium falciparum* is a major cause of morbidity and mortality worldwide. One of the striking features of this parasite is its ability to remodel and decrease the deformability of host red blood cells, a process that contributes to disease. To further understand the virulence of *Pf* we investigated the biochemistry and function of a putative *Pf* S33 proline aminopeptidase (*Pf*PAP). Unlike other *P. falciparum* aminopeptidases, *Pf*PAP contains a predicted protein export element that is non-syntenic with other human infecting *Plasmodium* species. Characterization of *Pf*PAP demonstrated that it is exported into the host red blood cell and that it is a prolyl aminopeptidase with a preference for N-terminal proline substrates. In addition genetic deletion of this exopeptidase was shown to lead to an increase in the deformability of parasite-infected red cells and in reduced adherence to the endothelial cell receptor CD36 under flow conditions. Our studies suggest that *Pf*PAP plays a role in the rigidification and adhesion of infected red blood cells to endothelial surface receptors, a role that may make this protein a novel target for anti-disease interventions strategies.

Index Key Words: prolyl aminopeptidase; malaria; *Plasmodium falciparum*; erythrocyte deformability; cytoadherence

1. Introduction

Parasites of the genus *Plasmodium* are the causative agents of malaria, man's most lethal parasitic disease. The World Health Organization estimates there were approximately 200 million clinical cases and 440,000 deaths due to malaria in 2015 (World Health Organization, 2015). While six *Plasmodium* species can infect humans, *Plasmodium falciparum* (*Pf*) is responsible for the majority of the morbidity and mortality of this disease (World Health Organization, 2015). The virulence of *Pf* malaria, while multi-faceted and not completely understood, is known to be associated with this parasite's ability to mediate the adherence of infected host red blood cells (RBCs) to the endothelium of micro-capillaries causing obstruction and preventing splenic clearance (Miller et al., 2002; Watermeyer et al., 2016). In essence *Pf* remodels host RBCs to facilitate endothelium adherence (reviewed in (Maier et al., 2009)). Remodeling involves the transport and deposition of exported parasite proteins including *Pf* erythrocyte membrane protein (*PfEMP*) 1 and knob-associated histidine-rich protein (KAHRP) to the host cell membrane (Maier et al., 2009; Watermeyer et al., 2016). RBC cytoskeletal modifications also occur (Cyrklaff et al., 2011; Shi et al., 2013). These host RBC modifications result in changes to RBC surface topology, membrane fluidity, permeability, adhesiveness and deformability (Aikawa, 1997; Atkinson and Aikawa, 1990; Cooke et al., 2004; Glenister et al., 2002; Maier et al., 2009; Nash et al., 1989; Watermeyer et al., 2016). However, the mechanisms driving all of these modifications remain unclear.

To further understand *Pf* mediated RBC remodeling and the virulence of *Pf* we have investigated the biochemistry and function of a putative S33 proline aminopeptidase (*PfPAP*). Unlike other plasmodial aminopeptidases (www.plasmodb.org) (Schoenen et al., 2010), *PfPAP* contains a predicted protein export element (PEXEL) (Marti et al., 2004) with the pentameric consensus sequence RILCD which is involved in facilitating the transport of parasite proteins into the host RBC. It is also non-syntenic with other human infecting *Plasmodium* species, suggesting a function unique to *Pf*

(www.plasmodb.org). While little is known about the biology and biochemical characteristics of S33 prolyl aminopeptidases (PAPs), they specifically release amino-terminal proline residues from peptides and are present in a variety of organisms/cells, including fungi (Bolumar et al., 2003), bacteria (Yoshimoto et al., 1999), plants (Waters and Dalling, 1983) and bovine kidney (Khilji et al., 1979). In addition they have been reported to act as virulence factors in some fungi which appear to use this exopeptidase to degrade proline-rich host proteins, such as collagen (Felipe et al., 2005). *Pf*PAP is a 473 amino acid protein characterized by an alpha/beta-hydrolase signature domain (aa 139-449) and an abhydrolase_1 alpha/beta hydrolase fold (aa 195-275). It also contains a PAP motif (aa 140-286), including the catalytic triad (S249, D402, H430) common to serine exopeptidase aminopeptidases. It is encoded by PF3D7_1401300, a two exon gene, with a predicted mRNA sequence of 1422 bp. Interestingly, PF3D7_1401300 is located on the left arm of chromosome 14 (www.plasmodb.org), in a region containing other genes whose protein products are exported into the RBC (Kyes et al., 1999).

2. Materials and Methods

2.1 *In silico* modeling

The protein sequence of *Pf*PAP was retrieved from PlasmoDB (www.plasmodb.org) using the gene ID PF3D7_1401300; a putative aminopeptidase. The sequence was aligned against a validated PAP from *Serratia marcescens*, PDB code 1QTR (Yoshimoto et al., 1999) using ClustalX (Larkin et al., 2007). No similarity was identified for the N-terminal PEXEL region of PF3D7_1401300 so this region was omitted to simplify the homology alignment and modelling process as well as to accelerate molecular dynamics simulations. A preliminary theoretical structural model of the protein was obtained by submission of the PEXEL truncated PF3D7_1401300 protein sequence to SwissModel, a fully automated protein structure homology-modelling server (<http://swissmodel.expasy.org/>). The initial structural refinement obtained automatically from within the SwissModel system was followed by a

comprehensive explicit solvent molecular dynamics simulation using periodic boundary water solvation and Particle mesh Ewald periodic electrostatic potentials for a total of 2 ns at 310 K, using the free parallel molecular dynamics code NAMD - a program designed and optimized for the high performance simulation of large biomolecular systems (Phillips et al., 2005).

2.2 Recombinant *Pf*PAP

Functional expression of *Pf*PAP was achieved using a truncated form of the enzyme lacking the PEXELated N-terminal Asn-rich repeat region (aa 1-92). This truncated coding sequence was chemically synthesized by GenScript (NJ, USA) using codons optimized for expression in *Escherichia coli* from the PlasmoDB annotated mRNA sequence (for PF3D7_1401300). The gene was cloned into the pTrcHis2B expression vector (Invitrogen, USA) and the construct verified by sequencing before transforming into Rosetta 2 BL21 cells. The cells were grown in 2YT media up to an OD of 0.6 and protein expression induced with 1 mM Isopropyl β -D-1-thiogalactopyranoside (IPTG) for 3 h at 30°C. Cells were lysed in 50 mM TrisHCl pH 7.5 containing 150 mM NaCl and 10 mM imidazole and extracted and solubilized with lysozyme and sonication. Hexa-histidine tagged recombinant *Pf*PAP was purified on a Ni-NTA-agarose column as previously described (Stack et al., 2007).

2.3 Enzymatic analysis

Recombinant *Pf*PAP activity and substrate specificity were determined by measuring the release of the fluorogenic leaving group, 7-amino-4methyl-coumarin (NHMeC) from the peptide substrate H-Pro-NHMeC. Reactions were carried out in 96-well microtiter plates (100 μ l total volume, 30 min, 37°C) using a multi-detection plate reader (BMG LABTECH FLUOstar OPTIMA) with excitation at 370 nm and emission at 460 nm. Initial rates were obtained over a range of substrate concentrations (1-2000 μ M) and at fixed enzyme concentration in 50 mM TrisHCl, pH 7.5. The pH

profile for recombinant *Pf*PAP was determined from the initial rates of H-Pro-NHMec hydrolysis carried out in constant ionic strength ($I = 0.1$ M) with acetate/Phosphate/Tris buffers, pH (5-10). Recombinant *Pf*PAP activity against the substrates H-Ala-NHMec, H-Leu-NHMec and H-Glu-NHMec was also examined.

2.4 Antibody production

Antibodies to recombinant *Pf*PAP were generated in Balb/c and C57/B6 mice by intraperitoneal injection of 50 µg of purified recombinant protein per mouse in 50 µl PBS mixed with an equal volume of complete Freund's adjuvant. This was followed by a further two immunizations at two week intervals with 50 µg recombinant protein in 50 µl PBS and an equal volume of incomplete Freund's adjuvant. Two weeks after the last injection test bleeds were performed and antibody titers to the recombinant protein measured by enzyme linked immuno-sorbent assay. Mice were then euthanized and blood collected by cardiac puncture.

2.5 Parasites

The *Pf* parasite clones 3D7 and D10 were cultured *in vitro* in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% human serum as previously described (Trager and Jensen, 1976). RBCs and pooled serum were obtained from the Red Cross Transfusion Service (Brisbane, QLD, Australia). *Pf*3D7 is a cytoadherent *Pf* clone possessing a complete chromosome 9, while D10 is a non cytoadherent *Pf* clone lacking the right arm of chromosome 9.

2.6 Northern blotting

Northern blotting was performed with total RNA extracts prepared using TRIzol (Invitrogen) as previously described (Kyes et al., 2000). Blots were probed with a purified 1504 bp PCR fragment

corresponding to the full length genomic copy of *PfPAP* amplified from genomic *Pf* DNA using primers PAPF (ATGAGAAATATTAATGGGT) and PAPR (TGTTTTATATTGACCATTTTT). Probes were labelled with [α -³²P] dATP by random priming (DECAprime II, Ambion Inc). The probe was hybridized overnight at 40°C in a hybridization buffer containing formamide (Northern Max; Ambion). The filter was washed once at low stringency and twice at high stringency (Northern Max; Ambion), then exposed to film overnight.

2.7 Quantitative real-time PCR

The stage specific expression of *PfPAP* was examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The *Pf* clonal line 3D7 was synchronized using two rounds of sorbitol treatment (Lambros and Vanderberg, 1979) (>99% early ring stage parasites) and parasites samples harvested at 0, 12, 18, 24, and 36 h. Transcript levels were assessed by extracting total RNA as previously described (Kyes et al., 2000) and generating cDNA (QuantiTect Reverse Transcription Kit, Qiagen). Quantitative PCR was performed using a Rotor-Gene 6000 real time PCR Cyclor (Corbett Research/Qiagen, Australia). Briefly cDNA was added to SYBR Green PCR Master-mix (Applied Biosystems, Australia) together with *PfPAP* specific primers (forward TCACCCGTTGGTGTATTGAA and reverse TGGTTACCACCATTCCCAAT) or internal reference primers (*18s rRNA*; PF3D7_0725600, forward CGGCGAGTACACTATATTCTTA and reverse TTAGTAGAACAGGGAAAAGGAT (Augagneur et al., 2012) or *Seryl-tRNA synthetase*, PF3D7_0717700, forward ATAGCTACCTCAGAACAACC and reverse CAAGATGAGAATCCAGCGTA (Roseler et al., 2012). Each run was performed in triplicate and repeated twice. Data were analysed with Rotor-Gene 6.0 software with *PfPAP* transcription calculated relative to both reference genes using the standard curve method and presented as mean $\pm$ SEM (Corbett Research/Qiagen, Australia).

2.8 Construction of the transgenic expression plasmids and parasites

PF3D7_1401300 was PCR amplified from *Pf* clone D10 genomic DNA using the forward primer PAPBglF (**AGATCT**ATGAGAAATATTAATGGGT; containing a *Bgl*II restriction site, in bold) and the reverse primer PAPPstR (**CTGCAGT**GTTTTATATTGACCATTTTT; containing a *Pst*I restriction site, in bold). The PCR product was cloned into pGEM using a TA cloning system (Promega, USA) and sequenced to confirm that no *Taq*-associated errors had occurred. Full length fragments were digested out of the pGEM vector using *Bgl*II and *Pst*I and subcloned into the previously digested (using *Bgl*II and *Pst*I) GatewayTM (InvitroGen) compatible entry vector pHGFPB . In this vector the introduced gene is ligated in frame with a 3' green florescent protein (GFP)-tag under the control of the heat shock protein 86 promoter (Dixon et al., 2008). This entry vector was designated pHB-PF1401300-GFP. A clonase reaction was then performed using this entry vector and a GatewayTM compatible destination vector with a destination cassette and a second cassette containing the human dihydrofolate reductase synthase gene under the control of the *Pf* calmodulin promoter as a selectable marker (conferring resistance to the anti-folate drug, WR92210). The final plasmid was designated pHH1-PF1401300-GFPB. For transfection, ring stage parasites were subjected to electroporation in the presence of 50 µg of plasmid DNA as described (Wu et al., 1995). Parasites resistant to WR99210 were obtained <25 days later.

2.9 Creation of knockout parasite clones

A transfection vector intended to disrupt the *Pf*PAP gene by double homologous recombination was designed using a positive negative selection strategy. This vector had previously undergone extensive modifications for use with the GatewayTM Cloning system. In the original modification the human dihydrofolate reductase synthase gene was used for positive selection and the Herpes simplex

thymidine kinase (*tk*) gene used for negative selection (sensitivity to ganciclovir). However in the current vector the *tk* gene was removed and replaced with the cytosine deaminase gene of *Escherichia coli*. This entry vector was then further modified by the addition of an *AvrII* site 10 bp from the unique *SalI* site upstream of the heat shock protein 86 promoter, allowing the insertion of the 5'-targeting sequence by directional cloning. The destination vector contained the human dihydrofolate reductase synthase gene under the control of the *Pf* calmodulin promoter and, downstream, the unique *AvrII/ClaI* cloning site. The 3'-targeting sequence was inserted into this site via directional cloning. A clonase reaction of the entry and destination vectors produced the final transfection vector (pHH1-*Pf*PAPDKO). Plasmid DNA was generated and transfected into *Pf* 3D7 parasites as previously described. Parasites resistant to WR92210 were detected 30 days post transfection. Parasites were cycled on both WR92210 and 5-fluoro-uracil until integration of the vector into the genomic copy of the *Pf*PAP gene was detected by PCR. These cultures were cloned by limiting dilution.

The pHH1-*Pf*PAPDKO transfection vector contained a 5'-targeting sequence generated by PCR amplification of DNA from *Pf* clone 3D7 using the primers PAPDKO5F (**CCTAGGCTTAAGTACATATGATAAACT**) and PAPDKO5R (**GTCGACAGGTTCAAATGCTTTAATAAT**). Restriction endonuclease sites are listed in bold. This generated a 739 bp fragment that was cloned into a pGEM Teasy vector (Promega), and sequenced. Digestion of this vector with the appropriate restriction endonucleases allowed directional cloning of the fragment into the entry vector. For the 3' targeting sequence a 641 bp PCR fragment was generated using the primers PAPDKO3F (**ATCGATTGGG ATGTATAATAGCCGCAG**) and PAPDKO3R (**CCTAGGTTA-TCAATAGTAATCTGTTT**). This PCR fragment was cloned into a pGEM Teasy vector (Promega), and sequenced to confirm the sequence. Digestion of this vector with the appropriate restriction endonucleases allowed directional cloning of the fragment into the destination vector.

2.10 Western Blotting

After washing infected RBCs in phosphate-buffered saline (PBS), parasites were released by incubation with 0.03% saponin in PBS at 4°C. Resulting parasite pellets were washed three times with PBS then lysed in distilled H₂O for 2 min, followed by centrifugation at 14,000 g. Parasite supernatants were stored at 4°C. Proteins of saponin-lysed parasite extracts were resolved on reducing 10% SDS-PAGE gels, transferred to a nitrocellulose membrane and probed with the anti-*Pf*PAP antisera (1:250 dilution) followed by a horseradish peroxidase-labelled anti-mouse IgG antibody (1:5000 dilution, Chemicon International Inc.). The membrane was stripped and re-probed with an anti-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) rabbit antibody (1:5000 dilution) to demonstrate transfer of malaria proteins (Spielmann et al., 2006).

2.11 Fluorescence Microscopy

Fluorescence and phase contrast images were collected with an Axioscope 2 Mot + (Zeiss) equipped with a Zeiss 63x/1.4 Plan Apochromat lens. Live parasites were mounted in PBS and observed at ambient temperature. Parasite DNA was visualized by adding Hoechst dye (0.5 µg/ml) and incubating at 37°C for 10 min prior to mounting. For indirect fluorescence, concanavalin A (0.5 mg/ml) was added to each well of a multi-well slide and incubated for 30 min at 37°C after which infected RBCs were added, incubated at room temperature for 15 min and unbound cells removed by washing with PBS. The cells were fixed in 4% formaldehyde/0.005% glutaraldehyde and probed with anti-*Pf*PAP anti-serum or with a mouse monoclonal antibody to GFP (diluted 1:500). Bound antibody was visualized with goat anti-mouse Ig-Cy2 (10 µg/ml). Immunofluorescence assays for the detection of KAHRP, Ring-exported protein-1 (REX1), and *Pf*EMP-3 were performed as previously described (Dixon et al., 2008). Briefly, thin blood smears of trophozoite stage parasites were made for both parent and *Pf*PAP knockout (PAPKO) cells, air dried and fixed in cold acetone for 10 min. Slides were

washed in 1X PBS and all antibody incubations were performed in 3% BSA 1X PBS for 1 h at room temperature. The following primary antibodies were used: anti-KAHRP mouse (1:500), anti-PfEMP-3 mouse (1:500) and anti-REX1 rabbit (1:2000). Slides were washed three times in 1X PBS prior to addition of anti-rabbit FITC and anti-mouse Alexa Fluor 647. Secondary antibodies were washed from the slides and the nuclei stained with 10 µg/ml of 4',6-diamidino-2-phenylindole (DAPI) prior to mounting of slides. Images were taken on a Delta Vision (DV) Elite Microscope with 100X oil objective. Images were processed using NIH ImageJ version 1.48c (<http://imagej.nih.gov/ij/>).

2.12 Atomic force microscopy

To investigate the mechanical properties of the infected and uninfected RBCs, arrays of 20 x 20 force curves on a 10 x 10 µm area were recorded on samples immersed in PBS employing an MFP-3D (Asylum Research) atomic force microscope (AFM) in force spectroscopy mode. The AFM was mounted on an anti-vibrational table (Herzan) and operated within an acoustic isolation enclosure (TMC, USA). The force curves were recorded using a SiNi cantilever (Budget Sensors, Bulgaria) having a nominal spring constant $K_N = 0.06$ N/m. Prior to use the cantilevers had been calibrated against a glass slide, using the thermal vibration method embedded in the AFM processing software. All experiments were repeated 4 times in triplicate with the loading force kept constant at 20 nN and the velocity at 1 µm/s. Force curve data were analysed using IGOR software. The Young's modulus, E , ($\pm$ SD) was calculated using the Hertz model.

2.13 Spleen mimic filtration

Parent 3D7 and 3D7-PAPKO parasites were synchronized to a 2 h window (Lambros and Vanderberg, 1979). Spleen mimic filtration was performed as previously described (Deplaine et al., 2011). Briefly, parasite infected RBCs at 5% parasitemia were re-suspended at 1% hematocrit in 1%

AlbuMax II in PBS. The solution was flowed over a 5 mm bead volume of calibrated metal microbeads ranging in size from 5-25 μm at a rate of 60 ml/h. The percentage parasitaemia pre and post filtration was assessed via Giemsa stained thin blood films and used to calculate the percentage of parasites present in the flow through (% flow). Three biological repeats were performed.

2.14 Cytoadherence assays

Cytoadherence assays were performed using prefabricated slides (ibidi GmbH). Slides were coated with 125 $\mu\text{g/ml}$ of recombinant CD36 in PBS overnight prior to blocking with 1% BSA for 1 h at 37°C. The slides were washed with RPMI-HEPES (minus NaHCO_3). All assays were performed on a DV elite microscope with environmental chamber set at 37°C.

Parasite infected RBCs at 3% parasitemia and 1% haematocrit in RPMI-HEPES (minus NaHCO_3) were flowed through the chamber for 5 min at a pressure of 0.1 or 0.05 Pa prior to a further washing (5 min) with RPMI-HEPES (minus NaHCO_3). Washing and counting was performed under the same conditions as binding. The number of parasite infected RBCs bound in 20 fields were counted, and expressed as parasites bound per mm^2 (Crabb et al., 1997). Three biological repeats were performed.

2.15 Electron microscopy

Parasite infected RBCs were embedded in 1% molten agarose in 0.1 M phosphate buffer. The agarose blocks were processed into Epon resin using a Pelco 34700 Biowave Microwave Oven (Ted Pella Inc., Redding, CA). Cells were post-fixed in aqueous potassium ferricyanide-reduced osmium tetroxide and dehydrated in ethanol prior to infiltration and embedment in Epon resin. Unstained ultrathin sections were observed and photographed using a JEOL 1011 transmission electron

microscope (JEOL Ltd, Tokyo, Japan) equipped with an Olympus Morada side-mounted digital camera (Olympus, USA).

3. Results

3.1 *In silico* modeling of *Pf*PAP

While no malaria parasite PAP structures currently exist in the protein data bank (PDB), X-ray derived solid-state structures of several other validated PAPs have been determined (<http://www.rcsb.org> (Berman et al., 2000)). To provide additional evidence that *Pf*PAP is indeed a PAP its amino acid sequence was aligned with a validated PAP derived from *Serratia marcescens* (Yoshimoto et al., 1999) (PDB code 1QTR; Fig 1, panels A, B and C; 41% similarity with *Pf*PAP; with specific N-terminal PEXEL sequence removed). Co-alignment of catalytically significant triad residues (Ser249, Asp402, His430) and other highly conserved residues, characteristic of PAPs, provided further evidence that *Pf*PAP belongs to this class of protein (Fig 1A). The primary sequence similarity observed in the alignment was also observed in the structural homology model. Comparison of the *Pf*PAP structural model with the X-ray derived structure of *S. marcescens* PAP (PDB code 1QTR) revealed that the spatial distributions of catalytic residues and other notable residues (Fig 1C) are highly conserved, further supporting the proposed function of PF3D7_1401300.

3.2 Biochemical characterization of functionally active recombinant *Pf*PAP

*Pf*PAP was expressed and purified as a recombinant protein (*rPf*PAP) from bacterial cells. The enzyme resolved as a single protein of ~45 kDa (Fig 2A) and immunoblotting confirmed expression of the recombinant protein (Fig 2B). Using the fluorogenic substrate H-Pro-NHMec (7-amido-4-methylcoumarin), *rPf*PAP exhibited a K_m of 403 μ M and a K_{cat}/K_m value 28.28 $M^{-1} s^{-1}$ (Fig 2C). Experiments investigating the specificity of *rPf*PAP demonstrate a low, but significant, level of activity

when incubated with the fluorogenic substrate H-Ala-NHMec (2-5% compared to H-Pro-NHMec) but no hydrolysis of H-Leu-NHMec or H-Glu-NHMec. When the metal chelator *o*-phenanthroline (2 mM) was added, only slight inhibition of r*Pf*PAP activity was observed, confirming the activity is specific and not due to contaminating bacterial neutral aminopeptidases (not shown).

3.3 *Pf*PAP is transcribed throughout the intraerythrocytic asexual lifecycle and exported into the host RBC

Northern blot analysis indicated that *Pf* transcribes a single species of mRNA with an apparent size of ~3 kbp throughout the intraerythrocytic life cycle (Fig 3A). Quantitative analysis of transcription suggested that peak expression occurs early in development (Fig 3B).

Western blot analysis of parent 3D7 parasites with anti-*Pf*PAP antiserum revealed a single species with an apparent molecular weight (MW) of ~40 kDa (Fig 3C). Immunochemistry using an anti-GFP antibody on a transgenic GFP-tagged *Pf*PAP chimeric protein also identified a single protein species (not shown). Immunofluorescence analysis using anti-*Pf*PAP antibody localized *Pf*PAP to the infected RBC cytoplasm which was confirmed in GFP-tagged *Pf*PAP transfected parasites (Fig 3D).

3.4 Targeted gene disruption (TGD) of *Pf*PAP changes the viscoelastic properties of the infected RBC membrane

PCR analysis indicated that a single homologous recombination of the 5' targeting sequence had occurred in the clone selected for further study. Nonetheless this led to a truncation of the genomic copy and Western blot analysis using antibodies to r*Pf*PAP indicated loss of *Pf*PAP expression (Fig 3C).

Genetic disruption of PF3D7_1401300 caused no obvious changes in macroscopic phenotype, including life cycle length, or in parasite viability *in vitro*. However, significant changes in the

viscoelastic properties of the infected RBC plasma membrane were observed using AFM. The Young's modulus value (E) was determined to be 760 ± 140 kPa for uninfected RBCs, and 1760 ± 710 kPa for 3D7 early trophozoite infected RBCs. However, 3D7_PAP-KO early trophozoite –infected RBCs generated a Young's modulus value of 800 ± 250 kPa. .

A microbead filtration system that mimics the splenic microcirculation was employed to assess RBC deformability changes in more detail (Fig 4A). Tightly synchronized parasites were analyzed 16, 18, 20 and 26 h post invasion. No significant difference between the percentage of 3D7 and 3D7_PAP-KO parasites in the flow through was seen at 16 h ($64 \pm 14\%$ vs $58 \pm 6\%$; relative to starting parasitemia). However, 3D7_PAP-KO parasites were significantly more filterable than 3D7 parasites at 18 to 26 h post-invasion (18 h: $64 \pm 4\%$ vs $41 \pm 5\%$; 20 h: $58 \pm 6\%$ vs $26 \pm 3\%$; and 26 h: $40 \pm 5\%$ vs $21 \pm 3\%$; $P = 0.0001$) (Fig 4A).

The impact of *Pf*PAP TGD on the expression and transport of proteins thought to play a role in the trafficking of unique *Pf* cytoadherence proteins, such as *Pf*EMP-1, to the infected RBC surface was assessed. Data demonstrated that TGD of *Pf*PAP does not change the location of KAHRP, ring-exported protein-1 (REX1), skeleton-binding protein-1 (SBP1) or *Pf*EMP-3. Each of these proteins was found at the RBC membrane or Maurer's clefts of 3D7 and 3D7PAPKO parasites (Fig 4B). Electron microscopy also confirmed the presence of electron dense structures at the infected RBC plasma membrane of both 3D7 (not shown) and 3D7PAPKO parasites (Fig 4C), consistent with correct trafficking and delivery of KAHRP.

The presence of *Pf*EMP-1 at the surface of both 3D7 and 3D7PAPKO parasites was demonstrated by trypsin cleavage (Fig 5A). Cleavage products (75-100 kDa) were observed in trypsin-treated (T) samples but were absent from samples with no trypsin (P) or with trypsin plus inhibitor (i) (Fig 5A). Consistent with these data parent 3D7 and 3D7_PAP-KO infected RBCs adhered to recombinant CD36 at similar levels under static conditions (Fig 5B). However, assessment of binding

under physiological flow conditions demonstrated that 3D7 infected RBCs bound at 500 ± 20 infected RBC/mm² while the 3D7_PAP-KO infected RBCs bound at a significantly lower rate (367 ± 16 infected RBC/mm²; $P < 0.0001$). This significant decrease in binding was also seen at the higher shear stress of 0.1 Pa. (Fig 5C).

4. Discussion

In this work PF3D7_1401300-encoded *Pf*PAP was verified as an aminopeptidase with a preference for N-terminal proline substrates and with a weaker specificity for substrates containing N-terminal alanine. While the fine specificities of various S33 clan members can vary, a weak specificity for N-terminal alanine is not uncommon in this group of enzymes. PAPs are not obligate proline aminopeptidases, with members being capable of cleaving additional residues including alanine (Mahon et al., 2009). A sequence comparison of *Pf*PAP with the well described PAP protein from *Serratia marcescens* (PDB code 1QTR) (Fig 1, panels A, B and C) also demonstrated the conserved location of catalytic triad residues in *Pf*PAP.

Particularly interesting features of *Pf*PAP are that it is unique to *Pf* and contains a protein export element (PEXEL) or vacuolar transit sequence (VTS) (www.plasmo.db.org). The presence of an export sequence suggests that unlike all other characterised *Pf* aminopeptidases, this enzyme is transported into the RBC cytoplasm. One of the important functions of exported proteins is to modify the host RBC membrane to facilitate adhesion to blood vessel walls, an event that underlies much of the pathophysiology of *Pf* infections. For example a number of exported parasite proteins facilitate the presentation of the adhesin, *Pf*EMP-1, at the RBC surface. They achieve this by reorganizing the host RBC membrane skeleton and by forming raised structures, known as knobs. The surface presentation of *Pf*EMP-1 at the knobby protrusions facilitates binding to endothelial receptors, such as CD36 (Crabb et al., 1997). Intra-erythrocytic maturation of *Pf* is also associated with RBC membrane rigidification

(Glenister et al., 2002). While KAHRP and *PfEMP-3* are responsible for about 50% of the observed rigidification (Glenister et al., 2002), it is recognized that other structural proteins and enzymes can contribute to the reorganization of the membrane skeleton and rigidification (Glenister et al., 2002; Sanyal et al., 2012).

To investigate the role of *PfPAP* in RBC re-modelling and cytoadherence we examined the expression and location of *PfPAP* within infected RBCs. We also performed a TGD of *PfPAP*. In these studies the expression of *PfEMP-1*, REX1, KAHRP and *PfEMP-3* was examined as was host RBC rigidity, deformability and CD36-mediated cytoadherence. Our data demonstrated that *PfPAP* is exported into the host RBC cytoplasm (Fig 3D) and that it is highly expressed early in the parasite asexual intra-erythrocytic life cycle (Fig 3B), characteristics that support a role in RBC remodeling. They also showed that while static CD36-mediated adhesion is not changed by *PfPAPKO*, adherence is weaker under flow conditions (Fig 5). In addition the rigidity and filterability (Fig 4) of host RBCs infected with parasites no longer able to express *PfPAP* is reduced when compared to wild-type parasites. Interestingly TGD of *PfPAP* had no impact on the delivery of KAHRP or *PfEMP-3* to the RBC membrane skeleton (Fig 4). It also had no impact on the delivery of REX1 or *PfEMP-1* to their known locations in the Maurer's clefts and RBC surface respectively (Figs 4 and 5).

While the precise role of the *PfPAP* remains to be elucidated, current data suggest that this protein plays a role in host RBC re-modelling independent of *PfEMP-1*, *PfEMP-3*, KAHRP and REX1 and that this role results in reduced RBC rigidity and cytoadherence under flow conditions. These data fit well with the non-essential nature of *PfPAP* *in vitro* where parasites are not dependent on cytoadherence and RBC deformability to survive. The ability of parasites to cytoadhere and avoid splenic clearance *in vivo* is of no advantage to parasites *in vitro*. Nevertheless, caution must be exercised before drawing firm conclusions in this regard. The current study did not investigate the expression of STEVOR (subtelomeric variant open reading frame) proteins in wild-type and transgenic

parasites and recent studies have demonstrated that these proteins play a role in the deformability of host RBCs infected with *Pf* gametocytes and asexual stages (Sanyal et al., 2012; Tiburcio et al., 2012). In addition, while the *Pf*EMP-1 variant expressed by both wild-type and *Pf*PAPKO parasites in this study demonstrated a comparable preference for CD36 under static conditions (Fig 5) further studies examining the impact of these variant proteins on RBC deformability and adherence under shear flow conditions were not performed, however care was taken to ensure that CD36 specific *Pf*EMP-1 binding variants were expressed by panning of parasites to CD36.

The current study verified PF3D7_1401300-encoded *Pf*PAP as a PAP and has provided the first insights into the functional role of this exported protease. Although further work including the analysis of additional clones, an assessment of expressed *stevor* genes in clones and an assessment of the impact of *var* gene expression on this protein's apparent role in RBC re-modelling is required to fully elucidate the role of *Pf*PAP in modifying the host RBC and to determine its contribution to survival fitness *in vivo*, the current data suggest that drugs designed to inhibit *Pf*PAP may be useful in preventing sequestration of the asexual stage in the micro-capillaries and warrants further investigation as an anti-disease drug target.

Acknowledgements

This work was supported by the National Health & Medical Research Council of Australia and the Australia Research Council (PD0666128).

References

- Aikawa, M., 1997. Studies on falciparum malaria with atomic-force and surface-potential microscopes. *Ann Trop Med Parasitol* 91, 689-692.
- Atkinson, C.T., Aikawa, M., 1990. Ultrastructure of malaria-infected erythrocytes. *Blood Cells* 16, 351-368.
- Augagneur, Y., Wesolowski, D., Tae, H.S., Altman, S., Ben Mamoun, C., 2012. Gene selective mRNA cleavage inhibits the development of *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 109, 6235-6240.
- Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., 2000. The Protein Data Bank. *Nucleic Acids Res* 28, 235-242.
- Bolumar, T., Sanz, Y., Aristoy, M.C., Toldra, F., 2003. Purification and characterization of a prolyl aminopeptidase from *Debaryomyces hansenii*. *Appl Environ Microbiol* 69, 227-232.
- Cooke, B.M., Mohandas, N., Coppel, R.L., 2004. Malaria and the red blood cell membrane. *Semin Hematol* 41, 173-188.

- Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, M.E., Brown, G.V., Coppel, R.L., Cowman, A.F., 1997. Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. *Cell* 89, 287-296.
- Cyrklaff, M., Sanchez, C.P., Kilian, N., Bisseye, C., Simporé, J., Frischknecht, F., Lanzer, M., 2011. Hemoglobins S and C interfere with actin remodeling in *Plasmodium falciparum*-infected erythrocytes. *Science* 334, 1283-1286.
- Deplaine, G., Safeukui, I., Jeddi, F., Lacoste, F., Brousse, V., Perrot, S., Biligui, S., Guillotte, M., Guitton, C., Dokmak, S., Aussilhou, B., Sauvanet, A., Cazals Hatem, D., Paye, F., Thellier, M., Mazier, D., Milon, G., Mohandas, N., Mercereau-Puijalon, O., David, P.H., Buffet, P.A., 2011. The sensing of poorly deformable red blood cells by the human spleen can be mimicked *in vitro*. *Blood* 117, e88-95.
- Dixon, M.W., Hawthorne, P.L., Spielmann, T., Anderson, K.L., Trenholme, K.R., Gardiner, D.L., 2008. Targeting of the ring exported protein 1 to the Maurer's clefts is mediated by a two-phase process. *Traffic* 9, 1316-1326.
- Felipe, M.S., Andrade, R.V., Arraes, F.B., Nicola, A.M., Maranhao, A.Q., Torres, F.A., Silva-Pereira, I., Pocas-Fonseca, M.J., Campos, E.G., Moraes, L.M., Andrade, P.A., Tavares, A.H., Silva, S.S., Kyaw, C.M., Souza, D.P., Pereira, M., Jesuino, R.S., Andrade, E.V., Parente, J.A., Oliveira, G.S., Barbosa, M.S., Martins, N.F., Fachin, A.L., Cardoso, R.S., Passos, G.A., Almeida, N.F., Walter, M.E., Soares, C.M., Carvalho, M.J., Brigido, M.M., PbGenome, N., 2005. Transcriptional profiles of the human pathogenic fungus *Paracoccidioides brasiliensis* in mycelium and yeast cells. *J Biol Chem* 280, 24706-24714.

- 463 Glenister, F.K., Coppel, R.L., Cowman, A.F., Mohandas, N., Cooke, B.M., 2002. Contribution of
464 parasite proteins to altered mechanical properties of malaria-infected red blood cells. *Blood* 99, 1060-
465 1063.
- 466 Khilji, M.A., Akrawi, A.F., Bailey, G.S., 1979. Purification and partial characterisation of a bovine
467 kidney aminotripeptidase (capable of cleaving prolyl-glycylglycine). *Mol Cell Biochem* 23, 45-52.
- 468 Kyes, S., Pinches, R., Newbold, C., 2000. A simple RNA analysis method shows var and rif multigene
469 family expression patterns in *Plasmodium falciparum*. *Mol Biochem Parasitol* 105, 311-315.
- 470 Kyes, S.A., Rowe, J.A., Kriek, N., Newbold, C.I., 1999. Rifins: a second family of clonally variant
471 proteins expressed on the surface of red cells infected with *Plasmodium falciparum*. *Proc Natl Acad Sci*
472 U S A 96, 9333-9338.
- 473 Lambros, C., Vanderberg, J.P., 1979. Synchronization of *Plasmodium falciparum* erythrocytic stages in
474 culture. *J Parasitol* 65, 418-420.
- 475 Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., Valentin,
476 F., Wallace, I.M., Wilm, A., Lopez, R., Thompson, J.D., Gibson, T.J., Higgins, D.G., 2007. Clustal W
477 and Clustal X version 2.0. *Bioinformatics* 23, 2947-2948.
- 478 Mahon, C.S., O'Donoghue, A.J., Goetz, D.H., Murray, P.G., Craik, C.S., Tuohy, M.G., 2009.
479 Characterization of a multimeric, eukaryotic prolyl aminopeptidase: an inducible and highly specific
480 intracellular peptidase from the non-pathogenic fungus *Talaromyces emersonii*. *Microbiology* 155,
481 3673-3682.

- 482 Maier, A.G., Cooke, B.M., Cowman, A.F., Tilley, L., 2009. Malaria parasite proteins that remodel the
483 host erythrocyte. *Nat Rev Microbiol* 7, 341-354.
- 484 Marti, M., Good, R.T., Rug, M., Knuepfer, E., Cowman, A.F., 2004. Targeting malaria virulence and
485 remodeling proteins to the host erythrocyte. *Science* 306, 1930-1933.
- 486 Miller, L.H., Baruch, D.I., Marsh, K., Doumbo, O.K., 2002. The pathogenic basis of malaria. *Nature*
487 415, 673-679.
- 488 Nash, G.B., O'Brien, E., Gordon-Smith, E.C., Dormandy, J.A., 1989. Abnormalities in the mechanical
489 properties of red blood cells caused by *Plasmodium falciparum*. *Blood* 74, 855-861.
- 490 Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D.,
491 Kale, L., Schulten, K., 2005. Scalable molecular dynamics with NAMD. *J Comput Chem* 26, 1781-
492 1802.
- 493 Roseler, A., Prieto, J.H., Iozef, R., Hecker, B., Schirmer, R.H., Kulzer, S., Przyborski, J., Rahlfs, S.,
494 Becker, K., 2012. Insight into the selenoproteome of the malaria parasite *Plasmodium falciparum*.
495 *Antioxid Redox Signal* 17, 534-543.
- 496 Sanyal, S., Egee, S., Bouyer, G., Perrot, S., Safeukui, I., Bischoff, E., Buffet, P., Deitsch, K.W.,
497 Mercereau-Puijalon, O., David, P.H., Templeton, T.J., Lavazec, C., 2012. *Plasmodium falciparum*
498 STEVOR proteins impact erythrocyte mechanical properties. *Blood* 119, e1-8.

- 499 Schoenen, F.J., Weiner, W.S., Baillargeon, P., Brown, C.L., Chase, P., Ferguson, J., Fernandez-Vega,
500 V., Ghosh, P., Hodder, P., Krise, J.P., Matharu, D.S., Neuenswander, B., Porubsky, P., Rogers, S.,
501 Skinner-Adams, T., Sosa, M., Spicer, T., To, J., Tower, N.A., Trenholme, K.R., Wang, J., Whipple, D.,
502 Aube, J., Rosen, H., White, E.L., Dalton, J.P., Gardiner, D.L., 2010. Inhibitors of the *Plasmodium*
503 *falciparum* M18 Aspartyl Aminopeptidase, Probe Reports from the NIH Molecular Libraries Program,
504 Bethesda (MD).
- 505 Shi, H., Liu, Z., Li, A., Yin, J., Chong, A.G., Tan, K.S., Zhang, Y., Lim, C.T., 2013. Life cycle-
506 dependent cytoskeletal modifications in *Plasmodium falciparum* infected erythrocytes. PLoS One 8,
507 e61170.
- 508 Spielmann, T., Gardiner, D.L., Beck, H.P., Trenholme, K.R., Kemp, D.J., 2006. Organization of
509 ETRAMPs and EXP-1 at the parasite-host cell interface of malaria parasites. Mol Microbiol 59, 779-
510 794.
- 511 Stack, C.M., Lowther, J., Cunningham, E., Donnelly, S., Gardiner, D.L., Trenholme, K.R., Skinner-
512 Adams, T.S., Teuscher, F., Grembecka, J., Mucha, A., Kafarski, P., Lua, L., Bell, A., Dalton, J.P.,
513 2007. Characterization of the *Plasmodium falciparum* M17 leucyl aminopeptidase. A protease involved
514 in amino acid regulation with potential for antimalarial drug development. J Biol Chem 282, 2069-
515 2080.
- 516 Tiburcio, M., Niang, M., Deplaine, G., Perrot, S., Bischoff, E., Ndour, P.A., Silvestrini, F., Khattab, A.,
517 Milon, G., David, P.H., Hardeman, M., Vernick, K.D., Sauerwein, R.W., Preiser, P.R., Mercereau-
518 Puijalon, O., Buffet, P., Alano, P., Lavazec, C., 2012. A switch in infected erythrocyte deformability at

the maturation and blood circulation of *Plasmodium falciparum* transmission stages. Blood 119, e172-180.

Trager, W., Jensen, J.B., 1976. Human malaria parasites in continuous culture. Science 193, 673-675.

Watermeyer, J.M., Hale, V.L., Hackett, F., Clare, D.K., Cutts, E.E., Vakonakis, I., Fleck, R.A., Blackman, M.J., Saibil, H.R., 2016. A spiral scaffold underlies cytoadherent knobs in *Plasmodium falciparum*-infected erythrocytes. Blood 127, 343-351.

Waters, S.P., Dalling, M.J., 1983. Purification and Characterization of an Iminopeptidase from the Primary Leaf of Wheat (*Triticum aestivum* L.). Plant Physiol 73, 1048-1054.

World Health Organization, 2015. World Malaria Report, World Health Organization, Geneva

Wu, Y., Sifri, C.D., Lei, H.H., Su, X.Z., Wellems, T.E., 1995. Transfection of *Plasmodium falciparum* within human red blood cells. Proc Natl Acad Sci U S A 92, 973-977.

Yoshimoto, T., Kabashima, T., Uchikawa, K., Inoue, T., Tanaka, N., Nakamura, K.T., Tsuru, M., Ito, K., 1999. Crystal structure of prolyl aminopeptidase from *Serratia marcescens*. J Biochem 126, 559-565.

Figure Legends

Fig 1. A sequence alignment was used to construct a theoretical structural model of the catalytic domain of PfPAP. A) ClustalX alignment of PF3D7_1401300 (N-terminal PEXEL region removed) against the prolyl aminopeptidase from *S. marcescens* (UniProtKB 032449). Catalytic triad residues

(S249, D402, H430) are highlighted. B) Crystal structure of prolyl aminopeptidase from *S. marcescens* (PDB code 1QTR). Catalytic residues are numbered and shown as Corey, Pauling, Koltun (CPK) surfaces. The protein backbone is shown as a thin tube. C). Initial model structure of the putative prolyl aminopeptidase PF3D7_1401300. Catalytic residues are numbered and shown as CPK surfaces. The protein backbone is shown as a thin tube.

Fig 2. Purification of a functionally active recombinant *Pf*PAP. A). Purification of active *rPf*PAP. M, molecular size markers; S, soluble supernatant; W, washes; E, eluted *rPf*PAP. Purified protein migrates at ~45 kDa. B). Immunoblot confirmed identity of eluted purified *rPf*PAP with primary mouse anti-histidine antibody and secondary goat anti-mouse horseradish peroxidase antibody. C). Enzyme assays with the fluorogenic peptide substrate H-Pro-NHMeC demonstrate that the *rPf*PAP exhibits typical Michaelis-Menten enzymatic kinetics with a K_m constant of 403.6 μ M.

Fig 3. *Pf*PAP is transcribed throughout the intraerythrocytic asexual lifecycle and exported into the host RBC. A). Northern blot analysis of PF3D7_1401300 transcription, RNA was probed with the full length coding region of the gene. R = ring stage parasites. ET = early trophozoite parasites, LT = late trophozoite parasites, S = schizont stage parasites. Analysis reveals transcription in all stages. B). Quantitative analysis of *Pf*PAP transcription relative to reference genes demonstrates highest transcription in early stages of the intra-erythrocytic asexual life cycle C). Western blot of 3D7 and 3D7_PAP-KO parasites probed with anti *Pf*PAP shows the loss of protein expression in the knockout line. REX1 protein expression in both clones was used to demonstrate protein loading. C). Direct fluorescence of transgenic parasites expressing PF3D7_1401300 C-terminally tagged with GFP. BF = bright field, GFP = GFP fluorescence, Nuclei = nuclear staining with Hoechst, Merge = merge of the previous images. Bar 5 μ m.

Fig 4. Targeted gene disruption of *Pf*PAP changes the filterability of the infected RBCs but not the expression or localization of KAHRP, REX1, and *Pf*EMP-3. A). Analysis of filterability of 3D7_PAP-KO through micro beads designed to mimic the splenic microcirculation. Samples were measured at 16, 18, 20 and 26 h post invasion. Data are presented as mean percentage of parasites present in the flow-through relative to the starting parasitemia ($\pm$ SEM; from 3 triplicate experiments). B). Immunofluorescence using anti-KAHRP, REX1, and *Pf*EMP-3 antibodies on 3D7 and 3D7_PAP-KO show no difference in the location of these proteins. C). Electron microscopy of 3D7_PAP-KO showing electron dense structures at the surface of the infected erythrocyte indicative of the presence of knobs. Bars are 5 μ m.

Fig 5. Targeted gene disruption of *Pf*PAP reduces CD36 cytoadhere under flow conditions A). Intact 3D7 and 3D7_PAP-KO infected RBCs were subjected to treatment with PBS (P) or trypsin (T) or trypsin plus inhibitor (i), then extracted and subjected to SDS-PAGE and probed using an antibody recognizing the ATS domain of *Pf*EMP-1. *Pf*EMP-1 cleavage products are indicated. B) 3D7 and 3D7_PAP-KO-infected RBCs adhere to recombinant CD36 at comparable levels under static conditions C). 3D7_PAP-KO parasites have a reduced ability to cytoadhere to CD36 under flow conditions. Adherence under flow conditions was assessed at flow rates equivalent to shear stresses of 0.1 and 0.05 Pa. The mean numbers (from 3 separate experiments) of parasites bound per mm² are shown ($\pm$ SEM).

A

```

PF140130 -----CPYEYGEVFGYGTGHIINYLKGNPESETLVIITFHGLYGSNLEFYBIQKF
1QTR      MEQLRGLYFFLAAYDSGLDTGDGHRIYWELSGNPNG-KPAVFIHGGPGGGISPHHRQLF
          ..* : * : * : * : * : * : * : * : * : * : * : * : * : * : * :
PF140130 LVKSNYQVLNFDLYGYGLSATPFYNDKEKTYGVDFYVEQTEELLKHLNLENKDYLLMGH
1QTR      DPER-YKVLFDQRCGRSRPHASLDNNTTWHLVADIERLREMA-----VEQWLVEGCS
          : : * : * : * : * : * : * : * : * : * : * : * : * : * :
PF140130 MGCIIAAGPTRRRHTEKVKHMLISPVGVLEKP-WYLK-----IFKRCCLINLSTFVL
1QTR      WGSTALAYAQTHPERVSEMVLREGIFTLRKQLHWYQUGASRFFPEKWERVLSILSDE
          * : * : * : * : * : * : * : * : * : * : * : * : * : * :
PF140130 RPFCEFSFKGRMVNGYDDDEEVLDIGNGGNNNSDDNDIYQNE--FLYNRLMWHLFVK
1QTR      RKDVIAAYRQLTS---ADFQVLEAAKLWSVWEGETVTLLPSRESASFGEDDFALAFAR
          * : * : * : * : * : * : * : * : * : * : * : * : * : * :
PF140130 KDNVAQSILGCINNLMWSAHIIYREVKGIG-IFVLILGSKIDCYCSEEVFENTSRYFRN
1QTR      IENHYFTHLGFL-----SDQLLRNVPLIRHIPAVIVHGRVMAQVQNAWDLAKAWPE
          : * : * : * : * : * : * : * : * : * : * : * : * : * :
PF140130 THLIIFDDASFLVLEETRKINMCTLLFFK--
1QTR      RELHIVEGAGSYDEPGILHQLMIATDRFAGK
          : * : * : * : * : * : * : * : * : * : * : * : * :

```

A

B

C

Substrate	H-Pro-NHMec
Kcat	0.0114 s ⁻¹ ± 0.0059
Km	403.5 ± 102.3 μM
Kcat/Km	28.277 M ⁻¹ s ⁻¹

A **B** **C**

A

B

C

- The pathology of *Falciparum* malaria is associated with the remodelling of host RBCs
- We investigated the role of *Pf*PAP, a putative proline aminopeptidase in this process
- *Pf*PAP contains a predicted protein export element and is non-syntenic with other malaria species
- Our data confirm that *Pf*PAP is a proline aminopeptidase that it is exported into the host RBC
- Genetic deletion of *Pf*PAP suggests it plays a role in RBC rigidification and cytoadhesion